Recurrent Pericarditis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Recurrent Pericarditis Market Outlook

Thelansis’s “Recurrent Pericarditis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Recurrent Pericarditis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Recurrent Pericarditis Overview

Recurrent Pericarditis, a syndrome characterized by the reappearance of pericardial inflammation symptoms after a symptom-free interval of 4–6 weeks following an acute pericarditis episode, is a significant medical concern. Various factors, including infections and autoimmune responses, can trigger this condition. The symptoms of recurrent Pericarditis encompass a dull ache, pressure, or stabbing chest pain that intensifies when coughing, taking deep breaths, or lying down. This pain, often mistaken for a heart attack, is alleviated by sitting up and leaning forward. Patients may also experience shortness of breath or difficulty breathing. This syndrome is the most challenging complication of acute Pericarditis, with 20% to 50% of patients experiencing recurrence within 18 months of the initial acute pericarditis episode. This can result in repeated hospitalizations and increased treatment costs. In approximately 85% of cases, the etiology remains idiopathic as it cannot be identified using standard laboratory techniques. Systemic diseases, including lupus erythematosus, Sjögren syndrome, rheumatic arthritis, scleroderma, and systemic vasculitis, among others, are often responsible for many recurrent cases. These diseases are well-known manifestations of recurrent Pericarditis. Consequently, Pericarditis is seldom the primary identified condition but is typically treated as part of the regimen for the accompanying disease. The typical treatment for recurrent Pericarditis involves aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs). If NSAIDs and colchicine fail to achieve complete remission, corticosteroids such as prednisone are prescribed in low to moderate doses.

• In the U.S., recurrent Pericarditis affects 15% to 50% of individuals with Pericarditis, approximately 40,000 people. The condition is most prevalent among males aged 16 to 65 years.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: